{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:22:02Z","timestamp":1788384122146,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"DOI":"10.7759\/cureus.78421","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:21:46Z","timestamp":1738592506000},"source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Sheenam","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansey","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Jatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheerja","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathima","family":"Wafa Eranhikkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Younas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le MH","year":"2022","unstructured":"Le MH, Yeo YH, Li X, et al.. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022, 20:2809-17.e28. 10.1016\/j.cgh.2021.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00317-x","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek J","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al.. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023, 8:20-30. 10.1016\/s2468-1253(22)00317-x","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso G","year":"2011","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011, 43:617-49. 10.3109\/07853890.2010.518623","journal-title":"Ann Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care","volume":"37","author":"Nogueira JP","year":"2024","unstructured":"Nogueira JP, Cusi K. Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care. Diabetes Spectr. 2024, 37:20-8. 10.2337\/dsi23-0013","journal-title":"Diabetes Spectr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher G","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020, 69:1691-705. 10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee QM","year":"2024","unstructured":"Anstee QM, Berentzen TL, Nitze LM, et al.. Prognostic utility of fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur. 2024, 36:100780. 10.1016\/j.lanepe.2023.100780","journal-title":"Lancet Reg Health Eur"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.022","article-title":"Performance of routine risk scores for predicting cirrhosis-related morbidity in the community","volume":"77","author":"Innes H","year":"2022","unstructured":"Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol. 2022, 77:365-76. 10.1016\/j.jhep.2022.02.022","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13939","article-title":"Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience","volume":"45","author":"Takyar V","year":"2017","unstructured":"Takyar V, Etzion O, Heller T, et al.. Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience. Aliment Pharmacol Ther. 2017, 45:744-53. 10.1111\/apt.13939","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30094","article-title":"Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database","volume":"68","author":"Allen AM","year":"2018","unstructured":"Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology. 2018, 68:2230-8. 10.1002\/hep.30094","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu V","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005, 128:1898-906. 10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"},{"key":"ref13","article-title":"Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD","volume":"8","author":"Alkhouri N","year":"2012","unstructured":"Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012, 8:661-8.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease","volume":"52","author":"Makri E","year":"2021","unstructured":"Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021, 52:25-37. 10.1016\/j.arcmed.2020.11.010","journal-title":"Arch Med Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","volume":"50","author":"Ajmera V","year":"2021","unstructured":"Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021, 50:101167. 10.1016\/j.molmet.2021.101167","journal-title":"Mol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121920","article-title":"Systematic review with meta-analysis: diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"9","author":"Mak AL","year":"2021","unstructured":"Mak AL, Lee J, van Dijk AM, et al.. Systematic review with meta-analysis: diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease. Biomedicines. 2021, 9:1920. 10.3390\/biomedicines9121920","journal-title":"Biomedicines"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71995-8","article-title":"A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis","volume":"10","author":"Dennis A","year":"2020","unstructured":"Dennis A, Mouchti S, Kelly M, Fallowfield JA, Hirschfield G, Pavlides M, Banerjee R. A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Sci Rep. 2020, 10:15308. 10.1038\/s41598-020-71995-8","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.127","article-title":"The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease","volume":"3","author":"Hernandez Roman J","year":"2020","unstructured":"Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab. 2020, 3:e00127. 10.1002\/edm2.127","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154259","article-title":"Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease","volume":"111S","author":"Long MT","year":"2020","unstructured":"Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism. 2020, 111S:154259. 10.1016\/j.metabol.2020.154259","journal-title":"Metabolism"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131664","article-title":"Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis","volume":"10","author":"Yang M","year":"2015","unstructured":"Yang M, Xu D, Liu Y, et al.. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One. 2015, 10:e0131664. 10.1371\/journal.pone.0131664","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson A","year":"2022","unstructured":"Andersson A, Kelly M, Imajo K, et al.. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin Gastroenterol Hepatol. 2022, 20:2451-61.e3. 10.1016\/j.cgh.2021.09.041","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison SA","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J, et al.. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020, 5:970-85. 10.1016\/s2468-1253(20)30252-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle M","year":"2019","unstructured":"Boyle M, Tiniakos D, Schattenberg JM, et al.. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 2019, 1:188-98. 10.1016\/j.jhepr.2019.06.004","journal-title":"JHEP Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.026","article-title":"ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD","volume":"76","author":"Corey KE","year":"2022","unstructured":"Corey KE, Pitts R, Lai M, et al.. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. J Hepatol. 2022, 76:25-33. 10.1016\/j.jhep.2021.09.026","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154005","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study","volume":"101","author":"Perakakis N","year":"2019","unstructured":"Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. Metabolism. 2019, 101:154005. 10.1016\/j.metabol.2019.154005","journal-title":"Metabolism"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed F","year":"2024","unstructured":"Abdelhameed F, Kite C, Lagojda L, et al.. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD. Curr Obes Rep. 2024, 13:510-31. 10.1007\/s13679-024-00574-z","journal-title":"Curr Obes Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/LVT.0000000000000450","article-title":"MRI-serum-based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: a multisite European study","volume":"0","author":"Schaapman J","year":"2024","unstructured":"Schaapman J, Shumbayawonda E, Castelo-Branco M, et al.. MRI-serum-based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: a multisite European study. Liver Transpl. 2024, 0:0. 10.1097\/LVT.0000000000000450","journal-title":"Liver Transpl"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine JG","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, et al.. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021, 19:2274-83.e5. 10.1016\/j.cgh.2020.08.061","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154958","article-title":"Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD","volume":"128","author":"Tang LJ","year":"2022","unstructured":"Tang LJ, Ma HL, Eslam M, et al.. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism. 2022, 128:154958. 10.1016\/j.metabol.2021.154958","journal-title":"Metabolism"},{"key":"ref30","unstructured":"Liver biopsy. (2024). Accessed. February 3, 2025: https:\/\/en.wikipedia.org\/wiki\/Liver_biopsy."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.7188","article-title":"The evolving role of liver biopsy in non-alcoholic fatty liver disease","volume":"17","author":"Arab JP","year":"2018","unstructured":"Arab JP, Barrera F, Arrese M. The evolving role of liver biopsy in non-alcoholic fatty liver disease. Ann Hepatol. 2018, 17:899-902. 10.5604\/01.3001.0012.7188","journal-title":"Ann Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31599","article-title":"NAFLD: reporting histologic findings in clinical practice","volume":"73","author":"Brunt EM","year":"2021","unstructured":"Brunt EM, Kleiner DE, Carpenter DH, et al.. NAFLD: reporting histologic findings in clinical practice. Hepatology. 2021, 73:2028-38. 10.1002\/hep.31599","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/330379-efficacy-of-non-invasive-biomarkers-in-diagnosing-non-alcoholic-fatty-liver-disease-nafld-and-predicting-disease-progression-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:21:49Z","timestamp":1738592509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/330379-efficacy-of-non-invasive-biomarkers-in-diagnosing-non-alcoholic-fatty-liver-disease-nafld-and-predicting-disease-progression-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.78421","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}